Tag: 3D Signatures
June 22, 2018
Big News Roundup: dynaCERT Announces New HG145 Orders and New Dealers; ChroMedX Announces Expansion and Launch as Relay Medical Corp.; OTC Markets Group Welcomes BioCure Technology Inc. to OTCQB
In case you missed it, here is this week's big news roundup in the Life Science sector.
May 10, 2018
3D Signatures Strengthens Its Intellectual Property With New Patents Issued for Tests in Alzheimer’s Disease, Hodgkin’s Lymphoma and Multiple Myeloma
3D Signatures Inc. (TSXV:DXD,OTCQB:TDSGF), a personalized medicine company with a proprietary software platform (TeloViewTM) based on the three-dimensional analysis of... May 4, 2018
Big News Roundup: Kalytera Announces Issuance of Second Patent Covering the Use of CBD in Graft Versus Host Disease; Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Zenabis
In case you missed it, here is this week's big news roundup in the Life Science sector.
April 19, 2018
Genetics Update: Q1 in Review
With Q1 2018 officially in the books, here the Investing News Network takes a look back at what some of... March 28, 2018
3D Signatures Collaborates with MDxHealth to Evaluate Telo-PC™ Test in Prostate Cancer
3D Signatures Inc. (TSXV:DXD,OTCQB:TDSGF) (the “Company” or "3DS"), a personalized medicine company with a proprietary software platform (TeloViewTM) based on... March 6, 2018
3D Signatures and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec Announce Collaboration
3D Signatures (TSXV:DXD) a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures, is... March 6, 2018
3D Signatures Inc. and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView™ with Genome Sequence Analysis in Lung Cancer
3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based... March 1, 2018
3D Signatures Reports Quarter Ended December 31, 2017 Financial Results
3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based... February 20, 2018
3D Signatures Announces Positive Topline Results of Development Trial Assessing its Telo-HL Test for Hodgkin’s Lymphoma
3D Signatures (TSXV:DXD) is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HL, 3DS’ test... February 20, 2018
